Titan Pharmaceuticals Inc

Titan Pharmaceuticals — Investor Presentation (June 2015)

21 slides from Titan Pharmaceuticals's investor presentation, Jun 15, 2015

  1. Slide 1: Corporate Presentation

    Corporate Presentation Sunil Bhonsle June 2015

  2. Slide 2: Safe Harbor

    Safe Harbor The presentation may contain “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Reference is made in particular to the description of our plans and objectives for future operations, assump

  3. Slide 3: Company Overview

    Company Overview Titan Pharmaceuticals specializes in the development of treatments for select chronic diseases utilizing its proprietary ProNeura ™ technology platform • ProNeura : Proprietary long - term Drug Delivery Platform ▫ Provides non - fluctuating medication levels over periods of six mont

  4. Slide 4: The Epidemic of Opioid Addiction

    The Epidemic of Opioid Addiction • Increasingly recognized as a global epidemic by world health authorities • Addiction - a primary, chronic disease of brain reward, motivation, memory and neurobiological circuitry ▫ Cravings, accompanied by lack of impulse control ▫ Abstinence is rarely a successfu

  5. Slide 5: Opioid Addiction: Treatment Overview

    Opioid Addiction: Treatment Overview Buprenorphine is the Gold Standard in the U.S., Replacing Methadone • Buprenorphine pharmacology makes it an effective, safer and more convenient treatment option ▫ Controls withdrawal symptoms and cravings without inducing opioid euphoria in patients ▫ Convenien

  6. Slide 6: Treatment of Opioid Addiction: Expanding the Market

    Sources : IMS Health, Wolters Kluwer Treatment of O pioid Addiction: Expanding the Market • Buprenorphine is the gold standard in the U.S., replacing Methadone ▫ U.S. sales of daily oral formulations of buprenorphine estimated at $1.7B in 2014 ▫ U.S. buprenorphine prescriptions have exceeded those o

  7. Slide 7: Proprietary ProNeura Technology: Probuphine Implant

    EVA polymer Buprenorphine Blended & Extruded Probuphine Proprietary ProNeura Technology: Probuphine Implant • Implant contains 80 mg of buprenorphine HCl , uniformly distributed throughout the ethylene vinyl acetate co - polymer (EVA) matrix • No reservoir, therefore no risk of drug dumping • Probup

  8. Slide 8: Probuphine Value Proposition

    Probuphine Value Proposition Probuphine is the first and only potential treatment for opioid addiction that provides non - fluctuating blood levels of buprenorphine around - the - clock for a period of six months 8 Titan Pharmaceuticals Company Overview | Proprietary & Confidential | ©2014 Titan Pha

  9. Slide 9: Probuphine Clinical and Regulatory Summary

    Probuphine Clinical and Regulatory Summary • Six clinical studies completed and NDA submitted in October 2012 ▫ Initial small dose finding study ▫ Two well controlled Phase 3 safety and efficacy studies showing clinical and statistical superiority over placebo and non - inferiority to Suboxone publi

  10. Slide 10: FDA Requested Phase 3 Clinical Study Completed (PRO-814)

    FDA Requested Phase 3 Clinical Study Completed (PRO 814) Randomized , double blind and double dummy design. Primary efficacy endpoint based on a non - inferiority comparison of ‘responders’ following six months of treatment with either a dose of four Probuphine implants or treatment with 8 mg or les

  11. Slide 11: Positive Top-line Phase 3 Study Results

    Positive T op - line Phase 3 Study Results ▫ 177 subjects randomized in the study and 173 subjects were included in the ITT population; 84 in the Probuphine arm and 89 in the sublingual buprenorphine/naloxone arm ▫ Primary endpoint of non - inferiority met with 81(96.4 %) responders in the Probuphin

  12. Slide 12: Probuphine: The First of its Kind

    Probuphine : The First of its Kind • NDA resubmission expected in the second half of 2015 with potential approval by the FDA in first half of 2016 • Peak sales potential: $300 - $500 mil in U.S. and partnership with Braeburn Pharmaceuticals for commercialization in U.S. and Canada ▫ Upfront: $15.75

  13. Slide 13: Titan: Adding Value Beyond Probuphine

    Titan: Adding Value Beyond Probuphine Proprietary ProNeura Technology Platform • L ong - term drug delivery technology validated through the Probuphine program • Potential for the treatment of select chronic diseases for which low dose long - term delivery and stable drug levels may offer advantages

  14. Slide 14: Parkinson's Disease Overview

    Definition Characterized by the loss of dopaminergic neurons which alters activity in the brain region impacting movement and motor function Treatment Treated with drugs designed to replace or mimic dopamine in the brain Following several years of chronic treatment, these drugs lose their benefit an

  15. Slide 15: Treated Population Increasing Worldwide

    Treated Population Increasing Worldwide 15 Based on information from Titan and other sources believed to be reliable and prepared exclusively for Titan. Woodside Capita l P artners is not responsible for any use that Titan may make of this material.

  16. Slide 16: Therapeutics Market

    Therapeutics Market • As many as one million people in the US affected by Parkinson’s disease • The number expected to almost double by 2030 because of the aging population • About 60,000 newly diagnosed for Parkinson’s disease annually • More than 23,000 die from Parkinson’s disease each year 16 Ti

  17. Slide 17: ProNeura Parkinson's Disease Program Non-clinical Proof of Concept

    ProNeura Parkinson’s Disease Program Non - clinical Proof of Concept • Ropinirole ( Requip ® ), a generic dopamine agonist marketed by GSK for PD, was evaluated in a Parkinsonian primate model using ProNeura technology • Results demonstrated: ▫ Sustained plasma ropinirole levels for several months f

  18. Slide 18: ProNeura Parkinson's Disease Program Next Steps

    ProNeura Parkinson’s Disease Program Next Steps In consultation with the Scientific Advisory Board: • Optimize implant formulation of ropinirole • Conduct non - clinical studies to support Investigational New Drug (IND) application • Design a proof of concept clinical study • Conduct a pre - IND mee

  19. Slide 19: Titan Executive Management

    • Marc Rubin, M.D, Executive Chairman and Director ▫ Eight years with Titan Pharmaceuticals. Former Head of Global Research & Development and member of the Board of Management at Bayer Pharma. Executive R&D and commercial responsibilities at GSK for 13 years. Twenty - five years in the pharmaceutica

  20. Slide 20: Titan Pharmaceuticals Summary

    Titan Pharmaceuticals Summary • Titan Pharmaceuticals specializes in the development of treatments for select chronic diseases, utilizing its innovative ProNeura technology platform • Probuphine , a six month buprenorphine implant for opioid addiction; R esubmission of NDA expected in the second hal

  21. Slide 21: Thank You

    Thank You Sunil Bhonsle June 2015

Titan Pharmaceuticals — Investor Presentation (June 2015) on 6ix